Kornimate/medical-research-clean huggingface dataset:
acute efficacy of exercises applied with xbox and biodex devices in pes planus"

Conditions: Pes Planus

Summary: .pes planus; it can be defined as the valgus of the hindfoot while loading the foot, the disappearance of the medial longitudinal arch in the midfoot, and the supination of the forefoot relative to the hindfoot. it may also occur due to the fact that the medial longitudinal arch in the foot is lower than the required height according to the anatomical position. the parts of the foot that touch the ground are anatomically healthy in a person; they are the heads of the calcaneus tuberositas calcanei on the back of the foot and the 5 metatarsal bones on the front of the foot. in the standing position, 25% of our body weight is on the tuber calcanei, while 25% is on the 5 metatarsal bones. in individuals with pes planus, convergence of the sole of the midfoot to the ground may even result in the sole of the midfoot touching the ground at its advanced levels. it is one of the common foot deformities.

pes planus can cause symptoms and dysfunction that are symptomatic or severe enough to limit patients' quality of life. degeneration of the posterior tibial tendon may occur due to trauma, neuroarthropathy, neuromuscular disease and inflammatory arthritis. among these, the most common cause of pes planus is the degeneration of the posterior tibial tendon. the highest arch of the foot, the medical longitudinal arch calcaneus, talus, navicular, cuneiform and 1-2-3. it is formed by metatarsals. it is effective in the distribution of the load on the feet. plantar ligaments are important in protecting the dome of the foot. they used many definitions known as pes planus, that is, flat feet in the literature. weak foot, relaxed foot, pes valgus, congenital hypermobile flat foot, hypermobile flat foot, flaccid flat food, talipes calcaneovalgus, compensated talipes equinus can be given as examples.

Eligibility criteria:
inclusion criteria: * having mild and moderate pes planus, * volunteering of individuals, * being between the age group of 18-25, * having experienced at least one inflammatory symptom (pain, swelling, etc.) * not having any systemic, locomotor and foot related diseases, sensory loss, diabetic and peripheral neuropathy. exclusion criteria: * having had a serious lower extremity injury in the last 6 months, * getting a full score from the balance test, * having ligament rupture in the ankle.

Keywords: pes planus exercise
efficacy and safety of quetiapine fumarate sustained release (seroquel sr) in combination with an antidepressant in the treatment of major depressive disorders

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to evaluate the efficacy of quetiapine sr in combination with an antidepressant versus an antidepressant alone in patients with mdd with inadequate response to an antidepressant treatment. please note: seroquel sr and seroquel xr refer to the same formulation. the sr designation was changed to xr after consultation with fda.


Eligibility criteria:
inclusion criteria: * patient is able to provide written informed consent before beginning any study related procedures * patient has a documented clinical diagnosis of major depressive disorder * patient is able to understand and comply with the requirements of the study, as judged by a study investigator exclusion criteria: * patients with a history of non-compliance as judged by the study investigator * patients with a known lack of response to previous treatment with quetiapine * patients who have participated in a clinical trial within 4 weeks of randomization

Keywords: mdd depression
complementary intradialytic nutritional supplementation in dialysis patients

Conditions: End Stage Renal Disease

Summary: in this study, the investigators hypothesize that long-term administration of adequate intradialytic oral nutritional supplementation will increase visceral protein concentrations and somatic protein stores in malnourished chronic hemodialysis patients.


Eligibility criteria:
inclusion criteria: 1. on hemodialysis for more than 6 months 2. optimally dialyzed with a biocompatible membrane (urr \> 70% and/or delivered kt/v \> 1.2) 3. suboptimal nutritional status identified by: * serum albumin less than or equal to 3.90 g/dl and one of the three following criteria: * protein catabolic rate less than 0.95 g/kg/d calculated by three point urea kinetic modeling on at least 2 occasions over the past 6 months * progressive unintentional weight loss more than 2.5% of the initial or ideal body weight over the past 6 months and/or patients who are less than 90% of standard body weight * biochemical parameters of malnutrition defined by 1 of 2 of the following measurements over the consecutive two months prior to inclusion: * serum transferrin concentration less than 225 mg/dl * serum prealbumin concentration less than 32 mg/dl exclusion criteria: 1. active auto-immune, inflammatory or infectious disease 2. documented malignancy within the last 12 months 3. patients on unusual dietary restrictions 4. life-expectancy less than 6 months 5. inability to tolerate nutritional supplements
adolescent self-management of type 1 diabetes: an intervention (completed)

Conditions: Adolescent Type 1 Diabetes

Summary: the goals of this r21 exploratory pilot and feasibility study were to: 1) design an internet-based self-management intervention for adolescents with type 1 diabetes; 2) test that intervention in a small randomized trial to establish technical feasibility, intervention acceptability, and competence in completing the necessary recruitment and research procedures. although not powered to detect statistically significant changes, possible outcomes of this study include improvements in problem-solving, coping, and self-management behaviors.


Eligibility criteria:
inclusion criteria:diagnosed for at least 6 months, age 13-17; internet access, parental consent - exclusion criteria: any sensory deficits that would preclude seeing or hearing. -

Keywords: type 1 diabetes, adolescent, self-management
integrated treatment protocol for acute malnutrition: a non inferiority trial in burkina faso

Conditions: Global Acute Malnutrition (GAM)

Summary: muac only is a pilot trial external control carried out between january 2017 and december 2017 in the yako district (northern region), burkina faso. the objective of this study is to evaluate an integrated protocol for acute malnourished children without medical complication. the hypotheses of the integrated protocol include : 1. a global treatment of acute malnutrition (moderate and severe) with a single treatment (rutf) would improve the functioning of the program through early identification of acutely malnourished children, while achieving a better coverage and using a single supply chain. 2. a gradual reduction of rutf dosage according to a child's muac status could significantly increase the number of children on treatment without increasing overall rutf quantity while maintaining similar recovery rates.

objectives : main objective : to ensure the recovery rate of the integrated protocol for treatment of acute malnutrition is significantly greater than 75% (reference value of the national program in bf). secondary objectives : * to ensure the mortality rate of the integrated protocol for treatment of acute malnutrition is significantly lower than 3% (reference value of the national bf program). * to ensure the default rate of the integrated protocol for treatment of acute malnutrition is significantly lower than 15% (reference value of the national bf program). * to ensure the non-response rate of the integrated protocol for treatment of acute malnutrition is significantly lower than 8%. * to ensure the hospitalization rate of the integrated protocol for treatment of acute malnutrition is significantly lower than 15%. * to ensure the coverage rate of the program increases by 30% after the year the integrated protocol was introduced (specific protocol annexed). * to estimate the relapse rate of the integrated protocol for treatment of acute malnutrition. * to compare rutf rations per child of the integrated protocol compared to the national protocol methods : the study population will include all acutely malnourished children aged between 6 and 59 months seeking consultations at all of the health centers in yako district between january 2017 and december 2017. the study will be implemented in burkina faso's yako district, which includes 54 health centers.

Eligibility criteria:
inclusion criteria: * being between 6 and 59 months old * new admission * acute malnutrition defined as follows: * muac\<125mm * muac\> 125mm and whz (z-score) \<-3 (who standard) * edema * resident in the study area (yako district) * signed informed consent of the mother or the child's guardian exclusion criteria: * children allergic to milk, peanuts and / or rutf

Keywords: muac acute malnutrition rutf children burkina faso
influence of brief supportive psychotherapy on major adverse cardiovascular events, neutrophil-lymphocytes ratio and psychological symptoms in acute coronary syndrome in intensive cardiac care unit

Conditions: Acute Coronary Syndrome; Brief Supportive Psychotherapy; Intensive Cardiac Care Unit

Summary: there was no mace in both groups, but there was stroke-major adverse vascular event lower in brief supportive psychotherapy group. there was neutrophil-lymphocytes ratio change better in brief supportive psychotherapy group and significantly in acute coronary syndrome patients without chronic heart failure or coronary arterial disease, also there was psychological symptom (depression) change better in brief supportive psychotherapy and significantly in acute coronary syndrome patients with chronic heart failure or coronary arterial disease.


Eligibility criteria:
inclusion criteria: * acute coronary syndrome * 》 18 years old * have got pharmacological treatment in cardiology standard with or without anxiolytic drug and had got or had not yet got pci * be able to communicate and ready to have interview, fill the questioners and psychotherapy exclusion criteria: * stroke * cardiogenic shock at admission time * psychosis * reject to involve in study

Keywords: brief supportive psychotherapy, acute coronary syndrome, major adverse cardiovascular events, neutrophil-lymphocytes ratio, psychological symptoms
dynamic ct imaging after nellix endoprosthesis implantation

Conditions: Aortic Aneurysm

Summary: the nellix endovascular sealing prosthesis (evas) endoprosthesis is a new device aimed at prophylactic treatment of abdominal aortic aneurysms. in regular follow up conventional ct-imaging is used for surveillance. in this study dynamic ct imaging in patients pre- and post-operative will be assessed for device changes and anatomical variances.


Eligibility criteria:
inclusion criteria: * nellix implantation exclusion criteria: * use of chimneys or combined with other stent graft material

Keywords: nellix evas evar dynamic ct dyna ct
substantial equivalence study for kai sensors rspot non-contact respiratory rate spot check

Conditions: Respiration

Summary: the purpose of this study is to determine whether the respiratory rate provided by the kai sensors rspot 100 non-contact respiratory rate spot check is as accurate as that provided by the welch allyn propaq encore model 242 and the embla embletta system with universal xacttrace respiratory effort sensor and somnologica for embletta software.

currently, medical professionals obtain respiratory rate for vital signs assessments either by counting the number of breaths during a 15, 30, or 60 second interval and multiplying to obtain breaths per minute, or by reading the respiratory rate off of a multiparameter vital signs monitor (such as a welch allyn propaq monitor), that provides respiratory effort information based on the change of ac impedance through ecg leads. the respiration channel (resp) of the welch allyn propaq is intended to detect the rate or absence of respiratory effort, deriving the signal by measuring the ac impedance between the selected terminals of the ecg electrodes. the rspot 100 non-contact respiratory rate spot check provides an alternative to the medical professional counting respiratory rate or reading the rate from a vital signs monitor designed for continuous respiratory rate monitoring. the kai sensors rspot 100 non-contact respiratory rate spot check is used for a one-time measurement of respiratory rate as part of a vital signs assessment in the hospital or other clinical settings. in this study, the rspot is operated simultaneously with two other systems that provide a respiratory rate: welch allyn propaq encore model 242 and embletta system with universal xacttrace and somnologica software. a respiratory rate is also obtained by counting respiratory excursions for the same duration as the rspot measurement interval, 15, 30, or 60 seconds. the rates obtained from each of the four measurement methods are then compared.

Eligibility criteria:
inclusion criteria: * adult \>18 years old * hospitalized on tower 6 or pauahi 6 or pauahi 4 * clinically stable * able to provide informed consent exclusion criteria: * clinically unstable 1. hypotensive requiring pressors or intra-aortic balloon pump 2. intubated 3. dyspnea or chest pain at rest 4. resting tachycardia (heart rate \>100 bpm) 5. requires supplemental (e.g., nasal canula or face mask) oxygen * scheduled or planned (e.g., ct scan, central line placement) procedure during the 30 minute study period

Keywords: non-contact radar respiratory respiration breathing rate frequency respiratory mechanics respiratory rate measurement
effect of dapagliflozin in patients with acute heart failure (dapa-response-ahf)

Conditions: Acute Heart Failure

Summary: dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (sglt2i), increases natriuresis alone and synergistically when combined with loop diuretics in patients with ahf without increasing renin angiotensin- aldosterone activity. thus, adding sglt2i to the standard loop diuretic therapy might confer additional decongestive and natriuretic benefits while avoiding the adverse electrolyte abnormalities and neurohormonal activation associated with other diuretic combination. these potential benefits may help with improved clinical outcomes, but clinical evidence is still lacking.


Eligibility criteria:
inclusion criteria: 1. adults aged 18 years or older who are hospitalized for hypervolemic ahf, with evidence of congestion defined as either: \* 2 of the following signs or symptoms: peripheral edema, ascites, jugular venous pressure \> 10mmhg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound. or \*if pulmonary artery catheterization is available, a pulmonary capillary wedge pressure greater than 19 mmhg plus a systemic physical exam finding of hypervolemia from the list above. 2. randomized within 24 hours of hospitalization for ahf 3. planned use of iv loop diuretic therapy during current hospitalization 4. estimated glomerular filtration rate (egfr) of at least 30 ml/min/1.73m2 by the mdrd equation 5. for diabetic patients, history of type 2 diabetes or a new hemoglobin a1c 6.5% on admission. exclusion criteria: 1. type 1 diabetes mellitus. 2. dyspnea primarily due to non-cardiac causes. 3. cardiogenic shock. 4. acute coronary syndrome within 30 days prior to randomization. 5. planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization. 6. signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (ph\>7.30 and glucose \>15 mmol/l and hco3\>18 mmol/l). 7. pregnant or nursing (lactating) women. 8. heart failure due to drug toxicity 9. adherence to medication less than 95%

Keywords: diabetic and non diabetic
a new approach to cervical cancer prevention in kenya

Conditions: Healthy

Summary: the purpose of this study is to determine if the human papillomavirus (hpv) deoxyribonucleic acid (dna) testing, performed on self-collected vaginal swabs, is acceptable, feasible, and sensitive and specific in detection of high-grade cervical lesions among kenyan women, compared to the current standard of care.

the purpose of this study is to test the hypothesis that effective cervical cancer screening can be performed in a high percentage of women, using hpv dna of self-collected vaginal samples, provided by women attending either chamas (community groups) or in their own homes. hpv dna testing will be used to triage women for a secondary screen by visual inspection with acetic acid (via) in a local clinic. the investigators will determine if hpv dna testing, performed on self-collected vaginal swabs, is acceptable, feasible, and sensitive and specific in detection of high-grade cervical lesions among kenyan women, compared to the current standard of care. in addition, women will bring their children to be vaccinated against hpv in these community meetings, using the standard of care for the approved hpv vaccine available in kenya. the investigators will test this approach by completing the following specific aims: specific aim 1: determine the percentage of women attending community meetings who will provide self-collected vaginal swabs for hpv dna testing. specific aim 2. following hpv dna screening using self-collected swabs, determine the percentage of these women who will attend the local clinic. specific aim 3. evaluate the statistical correlation between hpv dna testing of self-collected vaginal swabs and via (as all women in this pilot study will undergo via).

Eligibility criteria:
inclusion criteria: 1. women who live in kenya who are between the ages of 30 and 55, are willing to provide a self collected vaginal swab and willing to travel to the local clinic for a via exclusion criteria: 1. current pregnancy, inability to consent due to mental or physical disability, or a medical illness that has rendered the patient unable to understand consent

Keywords: human papillomavirus (hpv) cervical cancer prevention kenya
pharmacokinetic and safety study of daclatasvir in patients with renal impairment

Conditions: Hepatitis C

Summary: the purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of daclatasvir.

treatment, parallel assignment, open label, non-randomized, single dose adaptive design, pharmacokinetics study

Eligibility criteria:
inclusion criteria: - meet renal function criteria in one of four categories exclusion criteria: - unstable or uncontrolled medical conditions
a study of motexafin gadolinium (mgd) in combination with docetaxel and cisplatin for treatment of non-small cell lung cancer (nsclc)

Conditions: Non-Small-Cell Lung Carcinoma; Carcinoma, Bronchogenic

Summary: the purpose of the study is to determine the dose limiting toxicities and maximum tolerated dose of motexafin gadolinium when administered with docetaxel and cisplatin in patients with non-small cell lung cancer. a cycle consists of 3 weeks. during week 1, patients receive mgd, docetaxel, and cisplatin treatment followed by 2 weeks without treatment. eligible patients will receive 1 or 2 doses of mgd, depending on cohort, and a single dose of docetaxel and cisplatin at 75 mg/m² during the first week of each cycle. additionally, tumor response will be evaluated at the end of even numbered cycles (2, 4, and 6). patients may stay on the study a maximum of 6 cycles.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old * ecog score of 0, 1, or 2 * histologically confirmed diagnosis of non-small cell lung cancer exclusion criteria: laboratory values demonstrating inadequate function of the following: * bone marrow * kidneys * liver and * peripheral neuropathy grade 2 or higher * greater than 2 prior chemotherapy regimens

Keywords: non-small cell lung cancer lung cancer metastatic lung cancer inoperable lung cancer advanced lung cancer large-cell lung cancer adenocarcinoma, lung squamous cell carcinoma, lung squamous cell lung cancer large cell carcinoma, lung bronchogenic
azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in bangladesh

Conditions: Uncomplicated Falciparum Malaria

Summary: the purpose of this study is to investigate the efficacy of azithromycin combination therapy with artesunate for the treatment of uncomplicated falciparum malaria in bangladesh.

in view of spreading antimalarial drug resistance there is an urgent need for new combination treatments for a disease that kills more than one million people every year. azithromycin is a macrolide antibiotic that is particularly attractive due to its safety in children and experience with use in pregnancy. recent trials suggest that azithromycin has a strong potential as an antimalarial. the purpose of this study is to investigate the efficacy of azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in bangladesh.

Eligibility criteria:
inclusion criteria: 1. acute symptomatic falciparum malaria infection with a parasite density of 100 to 100,000 asexual parasites/ul as determined on the screening smear with fever (defined as ≥37.5ºc), or reported history of fever within the last 48 hours. 2. age: 8-65 years old 3. males or females. all females over the age of 12 are required to have a negative human chorionic gonadotropin (hcg) pregnancy test (urine). all females of childbearing potential (not surgically sterile, or less than two years menopausal) are required to use an acceptable method of contraception, such as implant, injectable, oral contraceptive(s) with additional barrier contraception, intrauterine device, sexual abstinence, or vasectomized partner, throughout the study 4. written informed consent obtained 5. willing to stay under close medical supervision for the study duration 6. otherwise healthy outpatients exclusion criteria: 1. pregnant women, nursing mothers, or women of childbearing potential who do not use an acceptable method of contraception (as described in inclusion criteria, #3) 2. mixed malaria infection on admission by malaria smear 3. a previous history of intolerance or hypersensitivity to the study drugs artesunate, azithromycin, or lumefantrine or to drugs with similar chemical structures 4. malaria drug therapy administered in the past 30 days by history 5. previous participation in this trial, or participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study 6. history of significant cardiovascular, liver or renal functional abnormality or any other clinically significant illness, which in the opinion of the investigator would place them at increased risk. 7. symptoms of severe vomiting (no food or inability to take food during the previous 8 hours). 8. signs or symptoms of severe malaria (as defined by who 2003) 9. unable and/or unlikely to comprehend and/or follow the protocol

Keywords: falciparum malaria therapy azithromycin artesunate coartem bangladesh
a study of efinopegdutide in healthy obese participants (mk-6024-015)

Conditions: Healthy

Summary: the goal of this study is to learn about the safety of efinopegdutide (mk-6024) and how well overweight healthy people tolerate it. researchers also want to know what happens to efinopegdutide in a person's body over time when taken as a single dose (part 1) or as multiple doses (part 2). in addition, the study will assess the amount of acetaminophen in the blood after receiving different strength doses of efinopegdutide (part 2 only).


Eligibility criteria:
inclusion criteria: the main inclusion criteria include but are not limited to the following: * is in good health * has body mass index (bmi) between 29 kg/m\^2 and 38 kg/m\^2 exclusion criteria: the main exclusion criteria include but are not limited to the following: * history of clinically significant endocrine, gastrointestinal (gi), cardiovascular (cv), hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * history of cancer (malignancy) * positive test(s) for hepatitis b surface antigen (hbsag), hepatitis c antibodies, or human immunodeficiency virus (hiv)